ArticleActa orthopaedica et traumatologica turcica2026
Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures.
Article in Acta orthopaedica et traumatologica turcica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe risk of symptomatic venous thromboembolism (VTE) following hip fracture surgery is estimated at 1%-6%, necessitating effective prophylactic measures. While aspirin has been widely used in total hip and knee arthroplasty due to its comparable efficacy, reduced bleeding risk, and cost-effectiveness, its role in trauma patients remains under researched. This study aims to evaluate the efficacy and safety of aspirin and enoxaparin for VTE prophylaxis in hip fracture patients.
methodsThis two-center, retrospective study analyzed 306 adult patients who underwent hip fracture surgery between 2019 and 2023. Patients were divided into 2 groups: the aspirin group (81 mg twice daily) and the enoxaparin group (40 mg subcutaneous once daily), both receiving prophylaxis for 4 weeks postoperatively. Demographics, comorbidities, surgical details, and clinical outcomes-including major bleeding events, symptomatic VTE (deep vein thrombosis and pulmonary embolism), periprosthetic joint infection (PJI), blood transfusion requirements, and 90-day mortality-were recorded. Statistical analyses were performed using Pearson chi-square and independent t-tests, with significance set at P < .05.
resultsThe aspirin group (n = 136) and enoxaparin group (n = 170) had mean ages of 67.66 Å} 19.67 and 63.42 Å} 19.71 years, respectively. Hemoglobin decrease was significantly lower in the aspirin group (1.75 Å} 1.07 g/dL vs. 2.73 Å} 1.56 g/dL, P = .001). In addition, the amount of postoperative blood transfusion was statistically significantly lower in the aspirin group compared to in the enoxaparin group (0.89 vs. 1.31 units, respectively, P = .034). There was no significant difference in mean hospital stay (6.84 vs. 6.65 days, P = .751). The incidence of major bleeding was higher in the enoxaparin group (3.7% (n = 5) vs. 5.3% (n = 9)), though not statistically significant (P = .789). Symptomatic VTE occurred in 3.7% (n = 5) of the aspirin group and 5.3% (n = 9) of the enoxaparin group (P = .453). Periprosthetic joint infection was observed in 2 patients in the enoxaparin group but none in the aspirin group (P = .447). Mortality within 90 days was lower in the aspirin group (8.8% (n = 12) vs. 15.9% (n = 27)), but the difference was not statistically significant (P = .066).
conclusionThis study suggests that aspirin appears to be a reasonable alternative to enoxaparin for VTE prophylaxis in hip fracture patients, demonstrating comparable efficacy with a lower blood transfusion requirement and similar rates of major bleeding and symptomatic VTE. Given its affordability, ease of administration, and favorable safety profile, aspirin appears to be a reasonable and costeffective alternative for high-risk trauma patients. Cite this article as: Korkmaz O, Hakyemez ÖS, Çakır N, et al. Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures. Acta Orthop Traumatol Turc. 2026; 60(2), 0305, doi: 10.5152/j.aott.2026.25305.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.